However, according to the results of the current clinical study, PD-1 mAbs have limited efficacy in CLL patients, but reassuringly they show a promising therapeutic option in patients with Richter’s transformation (140–142). This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.